Rashtriya Newsflash

Posts From admin

Biliary Atresia Market Emerging as a High-Growth Healthcare Investment Space Through 2034 – DelveInsight | Albireo Pharma, Mirum Pharma

The Key Biliary Atresia Companies in the market include – Intercept Pharmaceuticals, Albireo Pharma, Mirum Pharmaceuticals, and others.   The Biliary Atresia market is expected to surge due to the

Read Full Article

Type 2 Diabetes Pipeline 2026: FDA Updates, Therapy Innovations, and Clinical Trial Landscape Analysis by DelveInsight | Ionis Pharma, Eli Lilly, Oramed Pharma, AstraZeneca, Novo Nordisk

(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Type 2 Diabetes pipeline constitutes 75+ key companies continuously working towards developing 80+ Type 2 Diabetes treatment therapies, analysis of

Read Full Article

Pancreatic Cancer Market to Witness Transformational Growth Opportunities by 2036 – DelveInsight | Dragonfly Therapeutics, Tango Therapeutics, Atara Biotherapeutics, Keymed Biosciences, Carisma Therap

The Key Pancreatic Cancer Companies in the market include – AstraZeneca, Merck Sharp & Dohme, Actuate Therapeutics, Dragonfly Therapeutics, Keymed B, Tango Therapeutics, Atara Biotherapeutics, Keymed Biosciences Co.Ltd, Carisma Therapeutics

Read Full Article

Narcolepsy Market Trends, Innovation, and Future Growth Outlook to 2034 – DelveInsight | Taisho Pharmaceutical, Jazz Pharma, Suven Life Sciences Limited, Alza Corporation, Cephalon, Orphan Medical

  DelveInsight’s “Narcolepsy Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Narcolepsy, historical and forecasted epidemiology as well as the Narcolepsy market trends in the

Read Full Article

Metastatic HER2-positive Breast Cancer Market Set for Strong Expansion Through 2036 Amid Rising Investment Interest – DelveInsight | Ambrx, Zymeworks, Jazz Pharma, Roche, Criterium, Seagen, Sichuan

The Key Metastatic HER2-positive Breast Cancer Companies in the market include – MacroGenics, TerSera Therapeutics, Roche, Chugai, Daiichi Sankyo/AstraZeneca, Roche/Chugai,

Read Full Article

NASH Clinical Trial Pipeline Appears Robust With 70+ Key Pharma Companies Actively Working in the Domain | DelveInsight

DelveInsight’s, “Nonalcoholic Steatohepatitis Pipeline Insight, 2026” report provides comprehensive insights about 70+ companies and 75+ pipeline drugs in Nonalcoholic Steatohepatitis

Read Full Article

Antisense Oligonucleotide Therapeutics Clinical Trial Pipeline Gains Momentum: 70+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight

DelveInsight’s, “Antisense Oligonucleotide Therapeutics Pipeline Insights 2026” report provides comprehensive insights about 70+ companies and 90+ pipeline drugs in the

Read Full Article

Hemophilia Clinical Trial Pipeline Appears Robust With 50+ Key Pharma Companies Actively Working in the Domain | DelveInsight

DelveInsight’s, “Hemophilia Pipeline Insight, 2026” report provides comprehensive insights about 50+ companies and 55+ pipeline drugs in Hemophilia pipeline landscape.

Read Full Article

Pompe Disease Treatment Pipeline Shows Strong Momentum as 15+ Pharma Companies in the Race | DelveInsight

DelveInsight’s, “Pompe Disease Pipeline Insight 2026” report provides comprehensive insights about 15+ companies and 20+ pipeline drugs in Pompe Disease

Read Full Article

Prostate Cancer Clinical Trial Pipeline Expands as 140+ Companies Driving Innovation in the Therapeutics | DelveInsight

DelveInsight’s “Prostate Cancer Pipeline Insight 2026” report provides comprehensive insights about 140+ companies and 150+ pipeline drugs in the Prostate

Read Full Article